Cooper Investors PTY Ltd. Invests $4.31 Million in Halozyme Therapeutics, Inc. $HALO

Cooper Investors PTY Ltd. acquired a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the second quarter, Holdings Channel reports. The institutional investor acquired 55,023 shares of the biopharmaceutical company’s stock, valued at approximately $4,307,000. Halozyme Therapeutics accounts for about 2.0% of Cooper Investors PTY Ltd.’s portfolio, making the stock its 23rd biggest position.

Other institutional investors have also made changes to their positions in the company. Versant Capital Management Inc boosted its holdings in Halozyme Therapeutics by 37.3% during the second quarter. Versant Capital Management Inc now owns 1,693 shares of the biopharmaceutical company’s stock worth $133,000 after purchasing an additional 460 shares during the last quarter. Collective Family Office LLC increased its stake in Halozyme Therapeutics by 14.2% in the 2nd quarter. Collective Family Office LLC now owns 8,113 shares of the biopharmaceutical company’s stock valued at $635,000 after buying an additional 1,008 shares during the last quarter. Western Wealth Management LLC acquired a new stake in Halozyme Therapeutics in the 1st quarter valued at $229,000. Alpine Woods Capital Investors LLC bought a new stake in Halozyme Therapeutics during the 1st quarter worth about $281,000. Finally, Glenmede Trust Co. NA lifted its position in Halozyme Therapeutics by 22.4% during the 1st quarter. Glenmede Trust Co. NA now owns 146,717 shares of the biopharmaceutical company’s stock worth $9,482,000 after buying an additional 26,851 shares in the last quarter. Institutional investors own 97.79% of the company’s stock.

Insider Activity

In other news, CEO Helen Torley sold 1,923 shares of Halozyme Therapeutics stock in a transaction that occurred on Wednesday, July 8th. The stock was sold at an average price of $79.77, for a total transaction of $153,397.71. Following the completion of the transaction, the chief executive officer directly owned 767,780 shares in the company, valued at approximately $61,245,810.60. The trade was a 0.25% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of the stock in a transaction on Monday, June 29th. The shares were sold at an average price of $75.00, for a total value of $547,800.00. Following the completion of the sale, the director owned 14,462 shares in the company, valued at approximately $1,084,650. This trade represents a 33.56% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 72,477 shares of company stock valued at $5,102,643 over the last three months. Insiders own 2.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on HALO shares. Wall Street Zen upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. Weiss Ratings raised Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday. HC Wainwright reiterated a “buy” rating and set a $95.00 target price on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Morgan Stanley reduced their price target on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research report on Tuesday, May 12th. Finally, Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st. Eight investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $81.60.

Halozyme Therapeutics Stock Performance

Shares of HALO stock opened at $83.23 on Wednesday. The company has a fifty day moving average price of $75.09 and a two-hundred day moving average price of $71.07. Halozyme Therapeutics, Inc. has a one year low of $59.38 and a one year high of $84.44. The stock has a market cap of $9.87 billion, a P/E ratio of 29.94, a P/E/G ratio of 0.34 and a beta of 0.85. The company has a debt-to-equity ratio of 8.81, a current ratio of 2.76 and a quick ratio of 2.33.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.54 by $0.06. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The company had revenue of $376.71 million for the quarter, compared to analysts’ expectations of $358.60 million. During the same period in the prior year, the firm earned $1.11 EPS. Halozyme Therapeutics’s quarterly revenue was up 42.2% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. As a group, equities analysts predict that Halozyme Therapeutics, Inc. will post 7.54 EPS for the current year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.